Autologous bone marrow mononuclear cells transplant in patients with critical leg ischemia: Preliminary clinical results

Experimental and Clinical Transplantation

Volumn 11, Issue 5, 2013, Pages 435-439

  Li, Min ^a   Zhou, Hua ^a   Jin, Xing ^a   Wang, Mo ^a   Zhang, Shiyi ^a   Xu, Lei ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Autologous; Bone marrow mononuclear cells; Ischemia; Leg; Stem cell; Transplant

Indexed keywords

ADULT; ANKLE BRACHIAL INDEX; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; HEMODYNAMICS; HUMAN; HUMAN CELL; LEG AMPUTATION; LEG ISCHEMIA; LEG PAIN; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIAL; SKIN ULCER; SYMPTOMATOLOGY; TREATMENT RESPONSE;

AGED; ANKLE BRACHIAL INDEX; CHINA; CHRONIC DISEASE; CRITICAL ILLNESS; FEMALE; HEMODYNAMICS; HUMANS; ISCHEMIA; LEG ULCER; LOWER EXTREMITY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; PAIN; PAIN MEASUREMENT; RECOVERY OF FUNCTION; SINGLE-BLIND METHOD; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; WOUND HEALING;

EID: 84885601136     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: 10.6002/ect.2012.0129     Document Type: Article

References (14)

1. Isner JM, Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest. 1999;103(9):1231-1236.
2. Al-Khaldi A, Al-Sabti H, Galipeau J, Lachapelle K. Therapeutic angiogenesis using autologous bone marrow stromal cells: improved blood flow in a chronic limb ischemia model. Ann Thorac Surg. 2003;75(1):204-209.
3. Tang J, Xie Q, Pan G, Wang J, Wang M. Mesenchymal stem cells participate in angiogenesis and improve heart function in rat model of myocardial ischemia with reperfusion. Eur J Cardiothorac Surg. 2006;30(2):353-361.
4. Takahashi M, Li TS, Suzuki R, et al. Cytokines produced by bone marrow cells can contribute to functional improvement of the infarcted heart by protecting cardiomyocytes from ischemic injury. Am J Physiol Heart Circ Physiol. 2006;291(2):H886-H893.
5. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg. 2000;31(1 Pt 2):S1-S296.
6. Kusumanto YH, van Weel V, Mulder NH, et al. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum Gene Ther. 2006;17(6):683-691.
7. Rutherford RB, Becker GJ. Standards for evaluating and reporting the results of surgical and percutaneous therapy for peripheral arterial disease. Radiology. 1991;181(1):277-281.
8. Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997;26(3):517-538. Erratum in: J Vasc Surg 2001;33(4):805.
9. Durlik M, Olszewski WL. Biological effects of bone marrow in transplanted limb--a review. Ann Transplant. 2004;9(4):26-33.
10. Li WW, Talcott KE, Zhai AW, Kruger EA, Li VW. The role of therapeutic angiogenesis in tissue repair and regeneration. Adv Skin Wound Care. 2005;18(9):491-500; quiz 501-502.
11. Tateishi-Yuyama E, Matsubara H, Murohara T, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomized controlled trial. Lancet. 2002;360(9331):427-435.
12. Saigawa T, Kato K, Ozawa T, et al. Clinical application of bone marrow implantation in patients with arteriosclerosis obliterans, and the association between efficacy and the number of implanted bone marrow cells. Circ J. 2004;68(12):1189-1193.
13. Miyamoto K, Nishigami K, Nagaya N, et al. Unblinded pilot study of autologous transplantation of bone marrow mononuclear cells in patients with thromboangiitis obliterans. Circulation. 2006;114(24):2679-2684.
14. Hirsch AT. Critical limb ischemia and stem cell research: anchoring hope with informed adverse event reporting. Circulation. 2006;114(24):2581-2583.